Home › Markets › Health Care › WVE

Wave Life Sciences Inc. (WVE)

WVE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$3.14
-4.27% on the day
Market cap
$618.7M
Small cap
Revenue · 2025
$42.7M
-60.5% on 2024
Net income · 2025
-$204.4M
-478.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerWVE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySingapore
IPO year2015
SEC CIK0001631574
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$42.7M
Net income-$204.4M
Operating income-$215.4M
Net margin-478.3%
Operating margin-504.1%
Revenue growth-60.5%
Cash$602.1M
Total assets$638.5M
P/E (computed)Net income was not positive
P/S (computed)14.5×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-08-10
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-07-30
Latest current report8-K2026-07-30
Latest proxyDEF 14A2026-05-07

Source: SEC EDGAR submissions feed, 737 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-12.0%
1 month-30.2%
3 months-45.1%
Year to date-81.7%
1 year-60.0%
From 52-week high-85.4%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ZVRAZevra Therapeutics Inc.$10.39-8.22%$617.0M
OLMAOlema Pharmaceuticals Inc.$7.02-4.62%$614.2M
DSGNDesign Therapeutics Inc.$9.78-10.36%$612.0M
ABUSArbutus Biopharma Corporation$4.11-0.96%$630.0M
AVTXAvalo Therapeutics Inc.$12.01-9.29%$644.1M
IRWDIronwood Pharmaceuticals Inc.$3.59-4.52%$593.2M
CLYMClimb Bio Inc.$10.31-4.80%$592.2M
NVCTNuvectis Pharma Inc.$18.15-7.82%$591.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier